Crossmark

Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study

Crossref DOI link: https://doi.org/10.1007/s40123-022-00588-7

Published Online: 2022-10-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tang, Wenyi

Guo, Jingli

Xu, Gezhi

Liu, Wei https://orcid.org/0000-0001-6406-4722
Chang, Qing
Clinical Trials ^BETA

Clinical trials referenced in this document:

chictr2000038086 at Chinese Clinical Trial Registry

Documents that mention this clinical trial

Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study
https://doi.org/10.1007/s40123-022-00588-7
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82101150)

National Natural Science Foundation of China (82171078)

National Natural Science Foundation of China (81870670)

Shanghai Hospital Development Center (SHDC2020CR2041B)

Shanghai Hospital Development Center (SHDC2020CR5014-003)

Shanghai Sailing Program (21YF1405300)

Shanghai Science and Technology Development Foundation (20Y11911100)

Shanghai Science and Technology Development Foundation (18411965100)
License Information

Text and Data Mining valid from 2022-10-12

Version of Record valid from 2022-10-12
More Information

Article History

Received: 30 August 2022

Accepted: 28 September 2022

First Online: 12 October 2022

Document is current

Any future updates will be listed below